Priaxon Enters Collaboration with GSK on Protein-Protein-Interactions

Munich, Germany - 07 January 2013

Priaxon today announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modulation of protein-protein interactions (PPIs). PPIs play an important role in many cell signaling pathways and cell-surface receptor-ligand interactions that become dysregulated in disease states.


Risk-sharing between Pharma partner and Priaxon on agreed PPI-targets

  • Novel platform technology solely and exclusively applied on target from partner on risk sharing basisBased on a validated technology platform PriaXplore®